Michael Bulitta

Michael Bulitta

Auto-generated profile, based on publicly available information

Michael Bulitta

CRM Biometrics, Bornheim, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2012 in Critical Care
Verified
Journal Article
Open access
PPPeter Pickkers
Peter Pickkers
SHSuzanne Heemskerk
Suzanne Heemskerk
JSJeroen Schouten
Jeroen Schouten
PLPierre-François Laterre
Pierre-François Laterre
JVJean-Louis Vincent
Jean-Louis Vincent
JHJohannes G van der Hoeven
Johannes G van der Hoeven
Introduction: To evaluate whether alkaline phosphatase (AP) treatment improves renal function in sepsis-induced acute kidney injury (AKI), a prospective, double-blind, randomized, placebo-controlled study in critically ill patients with severe sepsis or septic shock with evidence of AKI was performed. Methods: Thirty-six adult patients with severe sepsis or septic shock according to Systemic Inflammatory Response Syndrome criteria and renal injury defined according to the AKI Network criteria were included. Dialysis intervention was standardized according to Acute Dialysis Quality Initiative consensus. Intravenous infusion of alkaline phosphatase (bolus injection of 67.5 U/kg body weight followed by continuous infusion of 132.5 U/kg/24 h for 48 hours, or placebo) starting within 48 hours of AKI onset and followed up to 28 days post-treatment. The primary outcome variable was progress in renal function variables (endogenous creatinine clearance, requirement and duration of renal replacement therapy, RRT) after 28 days. The secondary outcome variables included changes in circulating inflammatory mediators, urinary excretion of biomarkers of tubular injury, and safety. Results: There was a significant (P = 0.02) difference in favor of AP treatment relative to controls for the primary outcome variable. Individual renal parameters showed that endogenous creatinine clearance (baseline to Day 28) was significantly higher in the treated group relative to placebo (from 50 ± 27 to 108 ± 73 mL/minute (mean ± SEM) for the AP group; and from 40 ± 37 to 65 ± 30 mL/minute for placebo; P = 0.01). Reductions in RRT requirement and duration did not reach significance. The results in renal parameters were supported by significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to placebo. The Drug Safety Monitoring Board did not raise any issues throughout the trial. Conclusions: The improvements in renal function suggest alkaline phosphatase is a promising new treatment for patients with severe sepsis or septic shock with AKI. Trial Registration: www.clinicaltrials.gov: NCTNCT00511186

28 October 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HWHannes Weise
Hannes Weise
BZBenedikt Zenner
Benedikt Zenner
BSBettina Schmiedchen
Bettina Schmiedchen
LBLeo Benning
Leo Benning
MBMichael Bulitta
Michael Bulitta
KWKuno Weise
Kuno Weise
Background: The recommended first-line treatment for unspecific and degenerative back pain consists of movement exercises and patient education. Objective: Using a pragmatic, randomized controlled trial, we evaluated the effectiveness of a digital home exercise program on self-reported pain intensity compared with the standard of care for physiotherapy. Methods: Participant recruitment was based on newspaper advertisements and a consecutive on-site assessment for eligibility and enrollment. Participants with unspecific and degenerative back pain aged ≥18 years were randomly assigned in a 1:1 ratio to receive a 12-week stand-alone digital home exercise program or physiotherapy. The digital home exercise program included 4 exercises daily, while physiotherapy included 6 to 12 sessions, depending on the severity of symptoms. The primary outcome was pain, which was assessed using a verbal numerical rating scale. The clinical relevance of pain reduction was assessed using the following thresholds: improvement of at least 1.4 points on the verbal numerical rating scale and a pain reduction of at least 30%. Results: During the study period, 108 participants were assigned to the intervention group and 105 participants to the control group. The mean difference in pain scores between the 2 groups at 12 weeks was −2.44 (95% CI −2.92 to −1.95; P<.01) in favor of the intervention group. The group receiving the digital therapeutic achieved a clinically relevant reduction in pain over the course of the study (baseline vs 12 weeks), with a mean change of −3.35 (SD 2.05) score points or −53.1% (SD 29.5). By contrast, this change did not reach clinical relevance in the control group (mean −0.91, SD 1.5; −14.6%, SD 25.3). Retention rates of 89.9% in the intervention group and 97.3% in the control group were maintained throughout the study. Conclusions: The use of the app-based home exercise program led to a significant and clinically relevant reduction in pain intensity throughout the 12-week duration of the program. The intervention studied showed superior improvement in self-reported pain intensity when compared with the standard of care. Given the great demand for standard physiotherapy for unspecific and degenerative back pain, digital therapeutics are evolving into a suitable therapeutic option that can overcome the limitations of access and availability of conventional modes of health care delivery into this spectrum of indications. However, further independent evaluations are required to support the growing body of evidence on the effectiveness of digital therapeutics in real-world care settings. Trial Registration: German Clinical Trials Register DRKS00022781; https://tinyurl.com/hpdraa89

1 June 2002 in British Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
DWD Wetzel
D Wetzel
WMW Menke
W Menke
RDR Dieter
R Dieter
VSV Smasal
V Smasal
BGB Giannetti
B Giannetti
MBM Bulitta
M Bulitta
Objectives:To investigate the clinical efficacy and safety of escin-containing gels in the topical treatment of blunt impact injuries.Methods:Competitors in soccer, handball, or karate competitions were enrolled within two hours of sustaining a strain, sprain, or contusion and treated three times with the trial gel within a period of eight hours. Patients were randomised to three parallel groups consisting of two active treatment gels, containing escin (1% or 2%), 5% diethylammonium salicylate, and 5000 IU heparin, or placebo gel. Tenderness produced by pressure was measured at 0 (baseline), 1, 2, 3, 4, 6, and 24 hours after enrolment (within two hours of the injury). Tenderness was defined as the amount of pressure (measured by a calibrated caliper at the centre of the injury) that first produced a pain reaction as reported by the patient.Results:A total of 158 patients were enrolled; 156 were evaluated in the intention to treat analysis. The primary efficacy variable was the area under the curve for tenderness over a six hour period. The gel preparations containing 1% and 2% escin were significantly more effective (a priori ordered hypotheses testing controlling the multiple α = 5% significance level) than placebo (p1= 0.0001 and p2= 0.0002 respectively). The treatment effects were 5.7 kp h/cm2(95% confidence interval (CI) 2.9 to 8.5) and 5.9 kilopond (kp) h/cm2(95% CI 2.9 to 8.8) between 1% escin and placebo and between 2% escin and placebo respectively. These results were supported by secondary efficacy variables. The time to reach the baseline contralateral tenderness value (resolution of pain) at the injured site was shorter in the treatment groups than in the placebo group (p<0.0001). Both active gel preparations produced more rapid pain relief than the placebo gel. No relevant differences were detected between the two active gels. The safety and tolerability of the escin-containing gels were excellent.Conclusions:Escin/diethylammonium salicylate/heparin combination gel preparations are effective and safe for the treatment of blunt impact injuries.

20 February 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HWHannes Weise
Hannes Weise
BZBenedikt Zenner
Benedikt Zenner
BSBettina Schmiedchen
Bettina Schmiedchen
LBLeo Benning
Leo Benning
MBMichael Bulitta
Michael Bulitta
KWKuno Weise
Kuno Weise
[This corrects the article DOI: 10.2196/41899.].

2 June 2025 in Trials
Verified
Journal Article
Open access
PDF file
MWMarkus Wirth
Markus Wirth
JPJannik Pieper
Jannik Pieper
UHUlrike Heller
Ulrike Heller
MBMichael Bulitta
Michael Bulitta
DSDaniel Schmitz
Daniel Schmitz
SWStephan Wolpert
Stephan Wolpert
Background: Vestibular vertigo is one of the leading causes of disability. The clinical standard of care for vestibular vertigo includes physical activity producing central vestibular compensation (CVC). Home exercises are considered an integral part of physical therapy. However, a reliable solution is still needed to support the regular and correct execution of home exercises. For this purpose, VH-90-D DiGA was developed, which is a digital therapeutic (DTx) for multimodular in-home therapeutic training. Objective: The purpose of this study is to assess the clinical efficacy and safety of a vestibular health app for patients with vestibular vertigo. Methods: A randomized group-controlled single-blinded clinical trial (RCT) has been designed. Patients will be randomly assigned to one of two treatment groups and the endpoints examined in a pre-determined order. The experimental group receives the DTx (around 15 min/daily for 90 days), and the control receives physiotherapy according to the German statutory health care plan (usually 6 × 20 min of live physiotherapy). The primary outcome will be vertigo intensity measured using the German version of the validated Vertigo Symptom Scale-short form VSS-sf-VER (0–32 score points). Evaluation is performed after 2, 6, and 12 weeks. Primary outcomes are determined by measuring the group differences of the VSS-sf-score point changes from baseline to week twelve. Including dropouts, the sample size has been determined to be 2 × 100. Expected results: It is expected that therapy with the DTx will be statistically superior to physiotherapy in terms of effect size. Discussion: This trial protocol marks a confirmatory RCT (GEVE II) to investigate the efficacy and safety of a digital vertigo treatment. The planned RCT is based on a series of primary and secondary efficacy variables. Examination of the endpoints in a pre-determined order ensures the rigor of confirmatory statistics and addresses the challenge of multiplicity. This sequential testing continues until significance is achieved. However, if a specific variable fails to reach significance, subsequent variables will be explored solely on a descriptive basis. Trial registration: German National Registry of Clinical Studies (DRKS00028026), a WHO ICRTP registry. Registered on December 12, 2023.

14 February 2023 in JMIR Preprints
Verified
Preprint
Open access
HWHannes Weise
Hannes Weise
BZBenedikt Zenner
Benedikt Zenner
BSBettina Schmiedchen
Bettina Schmiedchen
LBLeo Benning
Leo Benning
MBMichael Bulitta
Michael Bulitta
KWKuno Weise
Kuno Weise
UNSTRUCTURED Addendum to the Acknowledgements is attached as a file.